Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.72 USD
Change Today +0.18 / 11.69%
Volume 16.5M
ENZN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

20 Kingsbridge Road

Piscataway, NJ 08854

United States

Phone: 732-980-4500

Fax:

Enzon Pharmaceuticals, Inc. is engaged in licensing drug products. The company receives royalties on six marketed drug products that utilize its proprietary PEGylation platform, namely PegIntron, Sylatron, Macugen, CIMZIA, Oncaspar and Adagen, with PegIntron being the major source of its royalty income. The company’s marketed drug products include PegIntron for chronic hepatitis C; Sylatron for Melanoma; Macugen for neovascular age-related macular degeneration; CIMZIA for Crohn’s disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. The company has out-licensed its proprietary PEGylation and single-chain antibody, technologies on its own and through agreements with Nektar Therapeutics, Inc. and Micromet AG. Macugen is being marketed by Valeant Pharmaceuticals Inc. in the U.S. and by Pfizer Inc. in the rest of the world. The company has a collaboration agreement with Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun) pursuant to which it licensed to Hisun exclusive development and commercialization rights for PEG-SN38 in China. Competition The company competes with Hoffmann-La Roche; Bayer; Bristol-Myers Squibb Company; Valeant Pharmaceuticals Inc.; Pfizer Inc.; UCB Pharma; Takeda; Affymax; and Amgen, Inc. History Enzon Pharmaceuticals, Inc. was founded in 1981.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $1.72 USD +0.18

ENZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abzena PLC 84.50 GBp 0.00
Nektar Therapeutics $10.77 USD -0.29
Onxeo SA €5.72 EUR -0.09
Regulus Therapeutics Inc $17.49 USD -0.80
Veloxis Pharmaceuticals A/S kr0.80 DKK -0.005
View Industry Companies
 

Industry Analysis

ENZN

Industry Average

Valuation ENZN Industry Range
Price/Earnings 2.6x
Price/Sales 2.4x
Price/Book 2.6x
Price/Cash Flow 2.6x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit www.enzon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.